GlassScriptPhysician profile
Katherine A Mclaughlin
NPI 1548662612
$3,717.29
in general payments reported to CMS, 2019-2025
10 companies · $2,868 in 2025
The $2,868 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.59 · 2024: $813 · 2025: $2,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.04 | 2024-2025 | |
| Lundbeck LLC | $459.70 | 2024-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $411.46 | 2024-2025 | Ajovy |
| Impel Pharmaceuticals LLC | $385.82 | 2024-2025 | Trudhesa |
| Pfizer INC. | $363.03 | 2024-2025 | |
| Axsome Therapeutics, INC. | $291.24 | 2025 | Symbravo |
| Lilly USA, LLC | $53.40 | 2024-2025 | Kisunla, Emgality, Reyvow |
| Amneal Pharmaceuticals LLC | $23.01 | 2025 | Brekiya |
| Alexion Pharmaceuticals, INC. | $19.27 | 2023 | Ultomiris |
| Ucb, INC. | $17.32 | 2023 | Fintepla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.